港股異動 | 科濟藥業(2171.HK)盤中大漲9%再度破頂 市值首次站上300億港元
格隆匯9月24日丨科濟藥業(2171.HK)延續強勢行情,盤中大漲9%,報53.05港元再度創下歷史新高價,總市值站上300億港元。公司日前在2021年ESMO年會上呈列CT041研究結果,CT041在臨牀前研究中顯示出抗原特異性抗腫瘤作用。在既往接受至少2線治療失敗的GC患者中,CT041的療效與歷史數據相比有顯著的改善。國泰君安此前表示,公司實體瘤有望全球率先突破,血液瘤緊跟世界步伐。首次覆蓋,給予增持評級。此外,公司獲納入港股通股票名單,已於本月初生效,推動公司的股東基礎及增加公司股份的交易流動性。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.